To be recognized as a quality, trustworthy, committed pharmaceutical company to in Cardiomeatabolic segment.
To generate net worth for its all stakeholders and business associates.
To achieve sustained sales, profit growth and a turnover of 100 Cr by 2020 through hard and committed work. 
Launch of speciality focused divisions for effective penetration in multiple specialities and market segment by 2020.